On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.

Cybin Corp. Leads Out in Growing Billion-Dollar Nutraceutical, Psychedelic Markets

  • Global nutraceutical market valued at $ 382.51 billion; psychedelic drugs market to reach $6.85 billion
  • Cybin deploys two-pronged approach covering both psychedelic pharmaceutical and nutraceutical segments
  • As psilocybin continues to prove effective in treating mental health conditions, the company is poised to leverage vast addressable market

Cybin Corp., a Canadian early-stage life sciences company appears ideally positioned in two promising markets: nutraceuticals and psychedelic drugs. Both sectors are projected to see impressive growth in the coming years. Cybin looks to benefit from its growing footprint in both spaces.

In 2019, the global nutraceutical market was valued at $382.51 billion. The market is also expected to grow at a compound annual growth rate (“CAGR”) of 8.3% over the next seven years. Consumers continue to embrace functional foods, or foods that offer benefits beyond basic nutrition, for their wellness benefits (http://nnw.fm/ofkid).

At the same time, the psychedelic drugs market is also projected to reach $6.85 billion by 2027. That forecast is based on increased incidences of mental health disorders as well as growing acceptance of psychedelic drugs. The expected proliferation of psychedelics comes from continued research interest from major academic institutions (http://nnw.fm/okHa0).

Cybin is committed to advancing research and development (R&D) through its intellectual property portfolio in the psychedelic, pharmaceutical and nutraceutical spaces. Based on the company’s unique psilocybin extraction methods, delivery mechanisms and new formulations, a variety of indications for mental health will be addressed.

The company’s business model is structured around two wholly owned divisions across the pharmaceutical and nutraceutical sector: Serenity Life Sciences and Nature’s Journey Inc. Serenity Life Sciences is focused on advancing R&D of psilocybin-based pharmaceutical products. Psilocybin, a naturally occurring, non-habit-forming psychedelic compound derived from mushrooms, is experiencing a strong research revival.

Studies show promising results in the treatment of a number of mental health conditions such as anxiety, depression, PTSD, addiction, eating disorders, ADHD and other conditions (http://nnw.fm/clSQE). Cybin views mushroom-derived psychedelic medicines as brain boosters potentially capable of breaking negative thought patterns. Studies indicate that retraining thought processes with low doses of psychedelics help with mental health conditions affecting hundreds of millions of people worldwide.

Cybin’s Nature’s Journey Inc. is focused on nonpsychedelic medical mushroom extracts. Consumer trend forecasts indicate that adaptogenic mushrooms are the next wave of super nutraceuticals. These products are designed to optimize overall health by enhancing mental wellness, immune-boosting detoxification and general well-being.

Cybin offers a robust, diversified business model with compelling growth opportunities in dual, complimentary sectors. Therefore, investors looking for high-potential investments in growing markets should take note of the company’s two-pronged approach to the psychedelic pharmaceutical and nutraceutical mushroom markets.

For more information about this company, please visit www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://nnw.fm/Cybin

About NetworkNewsWire

NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
212.418.1217 Office

NetworkNewsWire is part of the InvestorBrandNetwork.


Select A Month

NetworkNewsWire Currently Accepts



Bitcoin Cash

Bitcoin Cash





USD Coin

USD Coin

Contact us: 212.418.1217